Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
Non-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignant Lesions
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
- Status
- RECRUITING
- Phase
- PHASE3
5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC
- Status
- RECRUITING
- Phase
- PHASE2
Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC
- Status
- RECRUITING
- Phase
- PHASE2
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE2
A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors
- Status
- COMPLETED
- Phase
- PHASE1
A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection
- Status
- COMPLETED
- Phase
- PHASE3
CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Nivolumab for Recurrent/Metastatic Carcinosarcoma
- Status
- UNKNOWN
- Phase
- PHASE2
Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2